[Topical treatment of glucocorticoid-sensitive dermatoses with diflorasone diacetate].

Abstract

Treatment with diflorasone diacetate ointment and cream (0.05%) was strikingly successful in a multicenter clinical trial involving 4,651 patients in total suffering from various corticosteroid-sensitive dermatoses. According to the clinical evaluation, 93% of the patients were cured or much improved. Approximately 7% of the patients questioned rated the local tolerance of the two forms of administration as good to very good. Only 4% of the patients rated the tolerance of the ointment or cream as moderate or bad. None of the patients showed any systemic side-effects. The molecular structure of diflorasone-17,21-diacetate and the specific pharmaceutical properties of the ointment and cream evidently guarantee a good bioavailability of the glucocorticosteroid in the skin. Clinical and experimental results confirm that diflorasone diacetate belongs to the group of highly active corticosteroids.

• Authors: T A Rozman
• Journal: Zeitschrift fur Hautkrankheiten (Z Hautkr) Vol. 61 Issue 5 Pg. 294, 297-304 (Mar 01 1986) ISSN: 0301-0481 [Print] Germany
• Vernacular Title: Ausserliche Behandlung von Glukokortikoid-empfindlichen Dermatosen mit Diflorason-diacetat.
• PMID: 3962411 (Publication Type: Comparative Study, English Abstract, Journal Article)

Chemical References

• Betamethasone
• diflorasone

Topics

• Administration, Topical
• Adolescent
• Adult
• Aged
• Betamethasone (adverse effects, analogs & derivatives, therapeutic use)
• Child
• Dermatitis (drug therapy)
• Dermatitis, Atopic (drug therapy)
• Dermatitis, Contact (drug therapy)
• Eczema (drug therapy)
• Female
• Humans
• Male
• Middle Aged
• Psoriasis (drug therapy)
• Skin (drug effects)